Latest Sales Growth News

Unibail-Rodamco-Westfield reports robust H1-2025 results with tenant sales growth, portfolio valuation gains, and strategic brand expansion underpinning confidence in full-year earnings guidance.

Wellnex Life Limited reported a robust Q4 FY25 with a 22% sales increase and positive operational cash flow, underpinning its strategic growth initiatives backed by new debt funding.

Botanix Pharmaceuticals confirms material sales and prescription growth data, explaining the timing of its ASX disclosures amid share price fluctuations.

Michael Hill International reports flat full-year earnings and sales for FY25, with a second-half sales uptick and strategic store closures shaping its outlook.

Tasman Resources progresses exploration at Lake Torrens and Parkinson Dam projects while managing capital through a recent entitlement offer and loan repayments.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for TR987® despite patient recruitment hurdles, while TR Pro+® sales surge and new distribution deals pave the way for international growth.

Eden Innovations reports a striking 114% year-on-year jump in Q4 US sales of its EdenCrete® products, alongside a 50% annual sales increase and significant debt reduction plans.

Freehill Mining reported a transitional quarter marked by a dip in sales due to project cycles but offset by strategic site acquisitions and a successful capital raise. The company is poised for growth with new processing sites and promising magnetite test results.

Hydralyte USA reported an 8.5% rise in Q2 FY25 net sales, driven by strong May performance and improved margins, while preparing to launch new brain and gut health products.

FirstWave Cloud Technology reports a slight revenue decline in Q4 FY25, offsets challenges with strategic restructuring and a new AWS marketplace partnership.

Alexium International Group faced a tough FY25 with declining sales amid a soft US mattress market but is poised for growth in FY26 thanks to technological advances and strategic funding support.

ImpediMed Limited reported a record quarter for its SOZO device sales with $6.3 million in contracts, supported by expanded US reimbursement coverage and new funding. Despite stable revenue, the company’s cost-cutting and strategic moves position it well for growth in FY26.